EARS News and Press, Auris Medical Holding AG From 09/04/20

Tortoise Acquisition (NYSE: SHLL ) -9% . More news on: Tortoise Acquisition Corp., Auris Medical Holding Ltd., Digital Turbine, Inc., Stocks on the move, , Read more ...

Thinly traded nano cap Auris Medical ( EARS +27.7% ) jumps on a whopping 130x surge in volume in reaction to positive preliminary results from a Phase 2 clinical trial, TRAVERS , evaluating lead candidate AM-125 (betahistine) for the treatment of patients with acute peripheral vertigo f...

Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial Improvement 1.9 to 2.4 times greater with highest dose than with placebo Trial to proceed with Part B to test AM-125 10 and 20 mg vs. placebo   Hamilton, Bermuda, September 3, 2020 – Auris ...

Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has regained complianc...

Dose escalation completed as last patient enrolled into Part A of TRAVERS study Interim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address ...

Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gain Treatment well tolerated and safe with no adverse effects Enrollment into Phase 2 TRAVERS trial with AM-125 resumed following break due to COVID-19 pandemic Hamil...

Phase 1b trial with intranasal betahistine for prevention of antipsychotic-induced weight gain progressing towards final read-out Phase 2 trial with intranasal betahistine for treatment of acute vertigo progressing towards interim analysis, but temporarily slowed down by COVID-19 impact ...

Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020 Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemic Company to report 2019 second-half and full year results and provide general business update on April 16, 2020   Hamilton, B...

Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today highlighted the publication of an article descr...

Sorrento Therapeutics (NASDAQ: SRNE ) +50%  on non-binding takeover bid . More news on: Sorrento Therapeutics, Inc., Aclaris Therapeutics, Inc., AzurRx BioPharma, Inc., Stocks on the move, Read more ...